当前位置： SCI文献检索 > Thoracic Cancer期刊下所有文献 > Circulating tumor cells in the pulmonary vein increase significantly after lobectomy: A prospective observational study.

Circulating tumor cells in the pulmonary vein increase significantly after lobectomy: A prospective observational study.

Abstract：

BACKGROUND:It has been reported that there are more circulating tumor cells (CTCs) in the pulmonary vein (PV) than in the peripheral blood; however, it is unclear whether the CTC count changes in the PV after resection of a lung lobe. METHODS:Thirty-three lung cancer patients were recruited for the study, including 17 who underwent lobectomy via video-assisted thoracoscopic surgery and 16 via open thoracotomy. Sixty-six blood specimens were sampled from the PV before the PV was interrupted and after lobectomy. The CTCs were quantified using the oHSV1-hTERT-GFP method. RESULTS:Before PV interruption, the CTC (pre-CTC) detection rate was 79.0% (26/33), the mean number of CTCs was 3.36 (median 2, range: 0-18), and there was no significant relationship between the pre-CTC count and clinical factors, such as histologic findings and pathological T stage (P > 0.05). After lobectomy, the CTC (post-CTC) detection rate was 100% (33/33), the average number of CTCs was 14.88 (median 11, range: 1-69), and the post-CTC count was significantly higher in patients in whom the PV was interrupted prior to the pulmonary artery (PA) than in patients in whom the PA was interrupted before the PV (P = 0.016). Overall, the CTC count was significantly higher following surgery (P < 0.001). CONCLUSION:Post-CTC counts were significantly higher than pre-CTC counts, suggesting that surgical manipulation may potentially dislodge tumor cells into the PV. Interrupting the PV prior to the PA during lobectomy may prevent partial CTC entry into the circulation.

journal_name

Thorac Cancer

journal_title

Thoracic cancer

authors

Duan X,Zhu Y,Cui Y,Yang Z,Zhou S,Han Y,Yu D,Xiao N,Cao X,Li Y,Liu S,Wang Z,Zhang W,Feng L,Zhang K,Shou J,Liu Z,Xu S

doi

10.1111/1759-7714.12925

subject

Has Abstract

pub_date

2019-02-01 00:00:00

pages

163-169

issue

2

eissn

1759-7706

issn

1759-7714

journal_volume

10

pub_type

杂志文章

相关文献

Thoracic Cancer文献大全
  • Long-term survivor of pulmonary combined large cell neuroendocrine carcinoma treated with nivolumab.

    abstract：:Several authors have previously reported that patients with pulmonary combined large cell neuroendocrine cancer ( LCNEC) have a poor prognosis and there is no consensus on the treatment strategy for combined LCNEC as well as LCNEC. Here, we report the case of a long-term survivor with pulmonary combined LCNEC. The pat...

    journal_title：Thoracic cancer

    pub_type：

    doi：10.1111/1759-7714.13471

    authors： Oda R,Okuda K,Yamashita Y,Sakane T,Tatematsu T,Yokota K,Endo K,Nakanishi R

    更新日期：2020-07-01 00:00:00

  • Validated LC-MS/MS method of Sphingosine 1-phosphate quantification in human serum for evaluation of response to radiotherapy in lung cancer.

    abstract：BACKGROUND:Sphingosine 1-phosphate (S1P), a bioactive lipid, has been shown to mediate cancer processes. Therefore, accurate qualitative and quantitative determination is essential. The current assay method is still cumbersome to be of practical use worldwide and the aim of this study was therefore to develop a fast, a...

    journal_title：Thoracic cancer

    pub_type： 杂志文章

    doi：10.1111/1759-7714.13409

    authors： Tang X,Chen H,Chen G,Duan C,Fan Q,Li H,Wang Y,Li Z,Shi W,Liu Y

    更新日期：2020-06-01 00:00:00

  • MicroRNA-200b is a potential biomarker of the expression of PD-L1 in patients with lung cancer.

    abstract：BACKGROUND:Advanced non-small cell lung cancer (NSCLC) has a high mortality rate and poor prognosis. However, outcomes have gradually improved after the introduction of novel immunotherapies, including immune checkpoint inhibitors (ICIs). Although programmed death-ligand 1 (PD-L1) expression in tumor tissues is a known...

    journal_title：Thoracic cancer

    pub_type： 杂志文章

    doi：10.1111/1759-7714.13653

    authors： Katakura S,Kobayashi N,Hashimoto H,Kamimaki C,Tanaka K,Kubo S,Nakashima K,Teranishi S,Manabe S,Watanabe K,Horita N,Hara Y,Yamamoto M,Kudo M,Piao H,Kaneko T

    更新日期：2020-10-01 00:00:00

  • Retreatment with anti-PD-1 antibody in non-small cell lung cancer patients previously treated with anti-PD-L1 antibody.

    abstract：BACKGROUND:This study evaluated the efficacy and safety of retreatment with anti-programmed death 1 (anti-PD-1) antibodies in patients with advanced non-small cell lung cancer (NSCLC) after prior treatment with anti-programmed death-ligand 1 (anti-PD-L1) antibodies. METHODS:Data (N = 15) on patients' characteristics, ...

    journal_title：Thoracic cancer

    pub_type： 杂志文章

    doi：10.1111/1759-7714.13241

    authors： Fujita K,Yamamoto Y,Kanai O,Okamura M,Hashimoto M,Nakatani K,Sawai S,Mio T

    更新日期：2020-01-01 00:00:00

  • Fistula to the native esophagus after pharyngogastrostomy for malignant disease: A rare phenomenon in esophageal surgery.

    abstract：:This article features the case study of a 32-year-old female patient who had undergone surgery to remove a cervical spine tumor and who later developed cervical esophagus necrosis secondary to the erosion caused by an osteosynthesis 13 years after her prosthetic cervical surgery. Barium swallow did not show anything a...

    journal_title：Thoracic cancer

    pub_type：

    doi：10.1111/j.1759-7714.2012.00112.x

    authors： Hernández Hernández JR,Navarro Barlés G,López-Tomassetti Fernández EM,Vega Benítez V,Núñez Jorge V

    更新日期：2013-02-01 00:00:00

  • Endobronchial ultrasound-guided transbronchial needle aspiration and its role in non-small cell lung cancer: Diagnostic impact and limitations.

    abstract：:A diagnostic work-up to evaluate possible mediastinal lymph node involvement in patients with non-small cell lung cancer (NSCLC) should be performed once suspected as a result of computed tomography. Cytological/histological verification is always compulsory. In recent years, diagnostic tools for mediastinal evaluatio...

    journal_title：Thoracic cancer

    pub_type： 杂志文章,评审

    doi：10.1111/j.1759-7714.2010.00014.x

    authors： Dango S,Guenter J,Passlick B

    更新日期：2010-07-01 00:00:00

  • Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: A case report.

    abstract：:SMARCA4-deficient thoracic sarcoma (SMARCA4-DTS) is a new clinical entity characterized by SMARCA4 inactivation and has a dismal prognosis because of rapid growth. Effective treatments for SMARCA4-DTS have not yet been developed. Most recently, anti-programmed cell death 1 receptor (PD-1) blockade has been effective f...

    journal_title：Thoracic cancer

    pub_type：

    doi：10.1111/1759-7714.13215

    authors： Takada K,Sugita S,Murase K,Kikuchi T,Oomori G,Ito R,Hayasaka N,Miyanishi K,Iyama S,Ikeda H,Kobune M,Emori M,Kato J,Hasegawa T

    更新日期：2019-12-01 00:00:00

  • Factors related to rapid progression of non-small cell lung cancer in Chinese patients treated using single-agent immune checkpoint inhibitor treatment.

    abstract：BACKGROUND:Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of non-small cell lung cancer (NSCLC). While rapid progression (RP) has been proposed as a non-negligible pattern of response to ICIs, its definition and related factors remain unclear. This study aimed to develop a clinical definition of ...

    journal_title：Thoracic cancer

    pub_type： 杂志文章

    doi：10.1111/1759-7714.13370

    authors： Zhang L,Bai L,Liu X,Liu Y,Li S,Liu J,Zhang S,Yang C,Ren X,Cheng Y

    更新日期：2020-05-01 00:00:00

  • Duration of immunotherapy in patients with advanced lung adenocarcinoma with negative driver genes: case report and literature review.

    abstract：:Here, we report two cases of advanced non-small cell lung cancer (NSCLC) in patients with negative driver genes who received ICI treatment for less than two years but continued to benefit from their administration after drug withdrawal. The first patient was diagnosed with left lung adenocarcinoma, cT1cN3M1c, stage IV...

    journal_title：Thoracic cancer

    pub_type：

    doi：10.1111/1759-7714.13600

    authors： Shan Q,Wang H,Han X,Guo J,Wang Z

    更新日期：2020-10-01 00:00:00

  • Salvage surgery using simultaneous clamshell thoracotomy with median sternotomy for mediastinal growing teratoma syndrome.

    abstract：:This report describes the case of a 17-year-old man who developed mediastinal growing teratoma syndrome following two cycles of chemotherapy, after an initial diagnosis of primary mediastinal nonseminomatous germ cell tumor. The large, rapidly-growing mediastinal tumor was completely resected in conjunction with right...

    journal_title：Thoracic cancer

    pub_type：

    doi：10.1111/1759-7714.13297

    authors： Kao CN,Chou SH,Huang CL,Lin CH,Chiang HH,Lee JY,Li HP,Chang PC,Liu YW

    更新日期：2020-03-01 00:00:00

  • MicroRNA-128 promotes apoptosis in lung cancer by directly targeting NIMA-related kinase 2.

    abstract：BACKGROUND:MicroRNA-128 (miR-128) serves as a regulator by inducing cancer cell apoptosis, differentiation, the epithelial-to-mesenchymal transition process, and tumor growth by mediating different targets. NIMA-related kinase 2 (NEK2) is aberrantly expressed in lung cancer. The miR-128/NEK2 pathway has been reported t...

    journal_title：Thoracic cancer

    pub_type： 杂志文章

    doi：10.1111/1759-7714.12442

    authors： Zhao D,Han W,Liu X,Cui D,Chen Y

    更新日期：2017-07-01 00:00:00

  • Clinicopathologic characteristics, treatment outcomes, and prognostic factors of primary thoracic soft tissue sarcoma: A multicenter study of the Anatolian Society of Medical Oncology (ASMO).

    abstract：BACKGROUND:Soft tissue sarcomas (STSs) are rare malignant tumors of embryogenic mesoderm origin. Primary thoracic STSs account for a small percentage of all STSs and limited published information is available. This study aimed to identify the prognostic factors for thoracic STSs and evaluate the disease's clinical outc...

    journal_title：Thoracic cancer

    pub_type： 杂志文章

    doi：10.1111/1759-7714.12150

    authors： Unal OU,Oztop I,Yasar N,Urakci Z,Ozatli T,Bozkurt O,Sevinc A,Gunaydin Y,Yapar Taskoylu B,Arpaci E,Ulas A,Kodaz H,Tonyali O,Avci N,Aksoy A,Yilmaz AU

    更新日期：2015-01-01 00:00:00

  • Sebaceous-like clear cell changes in primary lung cancer.

    abstract：:We examined two cases of primary lung cancer with sebaceous-like clear cells (SLCCs), defined as clear carcinoma cells with microvacuolated cytoplasm and centrally located nuclei, which were selected from among 281 surgical/autopsy cases of lung cancer (2/281, 0.7%). Both cases were higher stage (stage IIA and IIIA), ...

    journal_title：Thoracic cancer

    pub_type：

    doi：10.1111/1759-7714.12004

    authors： Matsukuma S,Obara K,Kono T,Takeo H,Sato K

    更新日期：2013-11-01 00:00:00

  • Lung cancer surgery in HIV-infected patients: An analysis of postoperative complications and long-term survival.

    abstract：BACKGROUND:The purpose of this study was to investigate the risk factors of postoperative complications and reliable prognostic factors of long-term survival in HIV-infected patients with non-small cell lung cancer (NSCLC). METHODS:HIV-infected patients with NSCLC who underwent surgical treatment were retrospectively ...

    journal_title：Thoracic cancer

    pub_type： 杂志文章

    doi：10.1111/1759-7714.13519

    authors： Wang L,Chen Y,Wang Y,Liu J,Wen Z,Chen H,Zhu Y,Wang J,Wan L,Li F,Song Y

    更新日期：2020-08-01 00:00:00

  • SUMO1 promotes the proliferation and invasion of non-small cell lung cancer cells by regulating NF-κB.

    abstract：BACKGROUND:Our previous study showed that SUMO1 expression is closely related to progression in non-small cell lung cancer (NSCLC); however, the function of SUMO1 in NSCLC has not yet been well elucidated. METHODS:SUMO1 was enhanced or silenced in two NSCLC cell lines by using either forced SUMO1 expression or short h...

    journal_title：Thoracic cancer

    pub_type： 杂志文章

    doi：10.1111/1759-7714.12895

    authors： Ke C,Zhu K,Sun Y,Ni Y,Zhang Z,Li X

    更新日期：2019-01-01 00:00:00

  • Thoracoscopic completion right lower lobectomy after anteromedial basilar segmentectomy in early-stage lung cancer.

    abstract：:This report describes the surgical management of a male patient with early-stage lung cancer who underwent thoracoscopic completion right lower lobectomy after previously undergoing sublobar resection for multifocal ground glass nodules of the lung. Perioperative considerations associated with the management of dense ...

    journal_title：Thoracic cancer

    pub_type：

    doi：10.1111/1759-7714.13036

    authors： Liu YW,Chou SH,Hung JY,Kao CN,Chang PC

    更新日期：2019-05-01 00:00:00

  • Alteration in gene expression profiles of thymoma: Genetic differences and potential novel targets.

    abstract：BACKGROUND:This study was conducted to investigate the gene expression profiles associated with thymoma to better understand the molecular mechanism underlying the pathogenesis of thymoma. METHODS:Eight patients with thymomas (type A, AB, B1, and B2) and four controls with thymic cysts were analyzed using microarray p...

    journal_title：Thoracic cancer

    pub_type： 杂志文章

    doi：10.1111/1759-7714.13053

    authors： Meng FJ,Wang S,Zhang J,Yan YJ,Wang CY,Yang CR,Guan ZY,Wang CL

    更新日期：2019-05-01 00:00:00

  • Intensity of SLX predicts distance of tumor spread through alveolar spaces in stage I lung adenocarcinoma.

    abstract：BACKGROUND:Tumor spread through alveolar spaces (STAS) is a recently described invasive pattern associated with the prognosis and recurrence of lung adenocarcinoma. This study was performed to determine whether the presence and distance of STAS can be predicted by the immunohistochemical intensity of SLX, a well-known ...

    journal_title：Thoracic cancer

    pub_type： 杂志文章

    doi：10.1111/1759-7714.13008

    authors： Hara K,Mizuguchi S,Okada S,Izumi N,Tsukioka T,Komatsu H,Ohsawa M,Inaba M,Shibata T,Nishiyama N

    更新日期：2019-04-01 00:00:00

  • Clinical experiences with molecular targeted therapy in lung cancer in China.

    abstract：:In the past decade, a dramatic shift has been witnessed in cancer therapy in China. Although traditional cytotoxic chemotherapy still remains the treatment of choice for many malignancies, targeted therapies are now a component of treatment for many types of cancer, including lung cancer. As molecular target agents ar...

    journal_title：Thoracic cancer

    pub_type： 杂志文章,评审

    doi：10.1111/1759-7714.12243

    authors： Wang Y,Sun Y

    更新日期：2015-07-01 00:00:00

  • Case report of apatinib mesylate treatment in rare advanced tracheal adenoid cystic carcinoma.

    abstract：:A 57-year-old man was admitted to our department 10 years ago, diagnosed with tracheal adenoid cystic carcinoma. After discontinuing chemotherapy and radiotherapy, the disease recurred in December 2016. Apatinib mesylate (500 mg/day) was administered and computed tomography revealed that his symptoms were significantl...

    journal_title：Thoracic cancer

    pub_type：

    doi：10.1111/1759-7714.12506

    authors： Wang H

    更新日期：2017-11-01 00:00:00

  • Right upper lobectomy in lung cancer with double aortic arch: A case report.

    abstract：:Double aortic arch (DAA) is a rare congenital anomaly of the heart and aorta in which a vascular ring that surrounds the trachea and esophagus is formed. In most patients, respiratory distress and dysphagia develop in childhood, and asymptomatic adult patients are rarely known. Herein, we describe a patient with lung ...

    journal_title：Thoracic cancer

    pub_type：

    doi：10.1111/1759-7714.13545

    authors： Kawamoto N,Okita R,Inokawa H,Hayashi M,Furukawa M,Okada M,Okabe K

    更新日期：2020-08-01 00:00:00

  • EGFR exon 19-deletion aberrantly regulate ERCC1 expression that may partly impaired DNA damage repair ability in non-small cell lung cancer.

    abstract：BACKGROUND:Epidermal growth factor receptor (EGFR) activating mutations are usually associated with DNA damage repair (DDR) deficiency. However, the precise mechanism has remained elusive. In this study, we aimed to investigate whether EGFR exon 19 deletion mutation downstream signals contributed to DDR deficiency by d...

    journal_title：Thoracic cancer

    pub_type： 杂志文章

    doi：10.1111/1759-7714.13253

    authors： Zhang L,Pradhan B,Guo L,Meng F,Zhong D

    更新日期：2020-02-01 00:00:00

  • Pulmonary pleomorphic carcinoma: A case harboring EGFR mutation treated with EGFR-TKIs.

    abstract：:Pulmonary pleomorphic carcinoma (PPC) is a very rare type of primary lung cancer with an aggressive clinical course. Few reports have documented therapeutic options for PPC with EGFR mutations. Herein, we report a case of PPC with EGFR mutation treated with EGFR-tyrosine kinase inhibitors (TKIs). A 65-year-old Japanes...

    journal_title：Thoracic cancer

    pub_type：

    doi：10.1111/1759-7714.12646

    authors： Masuda K,Tokito T,Azuma K,Yanagida E,Nakamura M,Naito Y,Matsuo N,Ishii H,Yamada K,Akiba J,Hoshino T

    更新日期：2018-06-01 00:00:00

  • Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.

    abstract：BACKGROUND:ALK-tyrosine kinase inhibitors (TKIs) have been proven effective for treating ALK-positive non-small cell lung cancer (NSCLC), although patients present with variable responses and disease progression courses. The detailed underlying molecular mechanisms require further investigation to yield a better progno...

    journal_title：Thoracic cancer

    pub_type： 杂志文章

    doi：10.1111/1759-7714.12791

    authors： Kang J,Chen HJ,Zhang XC,Su J,Zhou Q,Tu HY,Wang Z,Wang BC,Zhong WZ,Yang XN,Chen ZH,Ding Y,Wu X,Wang M,Fu JG,Yang Z,Zhang X,Shao YW,Wu YL,Yang JJ

    更新日期：2018-09-01 00:00:00

  • Lung adenocarcinoma with anomalous bronchi and pulmonary veins preoperatively identified by computed tomography.

    abstract：:A 69-year-old woman visited our hospital complaining of right chest pain. Chest computed tomography showed a 55 × 45 mm tumor in the right upper lobe. Bronchoscopy revealed displaced anomalous B 1 and B 2+3 arising from the right main bronchus, and the patient was diagnosed with lung adenocarcinoma by transbronchial l...

    journal_title：Thoracic cancer

    pub_type：

    doi：10.1111/1759-7714.12362

    authors： Tajima K,Uchida N,Sasamoto H,Okada T,Kohri T,Mogi A,Kuwano H

    更新日期：2016-09-01 00:00:00

  • P16INK4a gene promoter methylation as a biomarker for the diagnosis of non-small cell lung cancer: An updated meta-analysis.

    abstract：BACKGROUND:This meta-analysis was conducted to investigate the diagnostic performance of P16INK4a gene promoter methylation as a biomarker of non-small cell lung cancer (NSCLC). METHODS:Two reviewers independently searched the Web of Science, PubMed, Cochrane, Embase, China National Knowledge Infrastructure, and Chine...

    journal_title：Thoracic cancer

    pub_type： 杂志文章,meta分析

    doi：10.1111/1759-7714.12783

    authors： Tuo L,Sha S,Huayu Z,Du K

    更新日期：2018-08-01 00:00:00

  • Drastic healing process after pembrolizumab monotherapy in a case of advanced squamous cell carcinoma with severe bronchial stenosis observed over a two-year period using continuous bronchoscopy: A case report.

    abstract：:Programmed cell death-1 immune checkpoint inhibitor (ICI) antibody has proven to be effective in advanced non-small cell lung cancer (NSCLC) patients positive for programmed cell death-1 ligand-1. However, there are currently no reports which evaluate drug efficacy by continuous bronchoscopic observation. A 75-year-ol...

    journal_title：Thoracic cancer

    pub_type：

    doi：10.1111/1759-7714.13390

    authors： Morikawa K,Kida H,Handa H,Inoue T,Miyazawa T,Mineshita M

    更新日期：2020-05-01 00:00:00

  • Clinical characteristics and risk factors of drug-induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis.

    abstract：BACKGROUND:If anaplastic lymphoma kinase (ALK) gene rearrangement in lung cancer is identified, ALK-tyrosine kinase inhibitors (ALK-TKIs) can be an effective treatment. However, the details of drug-induced lung injury (DILI) caused by ALK-TKI, which can be a serious side effect of ALK-TKIs, remains unclear. This study ...

    journal_title：Thoracic cancer

    pub_type： 杂志文章

    doi：10.1111/1759-7714.13416

    authors： Koshikawa K,Terada J,Abe M,Iwasawa S,Sakayori M,Yoshioka K,Hirasawa Y,Kasai H,Kawasaki Y,Tsushima K,Tatsumi K

    更新日期：2020-06-01 00:00:00

  • Surgeons' preference sublobar resection for stage I NSCLC less than 3 cm.

    abstract：BACKGROUND:This study aimed to compare survival between standard lobectomy and surgeons' preference sublobar resection among patients with stage I non-small cell lung cancer (NSCLC). METHODS:Medical records of patients undergoing pulmonary resection between 2006 and 2016 were reviewed retrospectively. Differences in d...

    journal_title：Thoracic cancer

    pub_type： 杂志文章

    doi：10.1111/1759-7714.13336

    authors： Huang CS,Hsu PK,Chen CK,Yeh YC,Hsu HS,Shih CC,Huang BS

    更新日期：2020-04-01 00:00:00

  • Lung adenocarcinoma initially presenting as Trousseau's syndrome treated successfully with pembrolizumab: A case report.

    abstract：:A 60-year-old woman was urgently admitted to our hospital because of vertigo and left hemiplegia. Laboratory examination showed thrombocytopenia, high levels of D-dimer and carcinoembryonic antigen. Brain magnetic resonance imaging (MRI) revealed multiple bilateral cerebral infarctions. Chest computed tomography (CT) ...

    journal_title：Thoracic cancer

    pub_type：

    doi：10.1111/1759-7714.13794

    authors： Nakano Y,Koide N,Koyama Y,Nitta K,Koizumi T

    更新日期：2020-12-21 00:00:00